SCOLR May File NDA For Ibuprofen Product Following Break With Wyeth
This article was originally published in The Tan Sheet
Executive Summary
SCOLR Pharma will either file an NDA with FDA or work with another pharmaceutical company to develop its 12-hour extended-release ibuprofen product after Wyeth announced it will terminate an agreement with the firm effective April 16